Abstract
Fatty acid amide hydrolase (FAAH) is an enzyme that degrades anandamide, an endocannabinoid that modulates mesolimbic dopamine release and, consequently, influences states of well-being. Despite these known interactions, the specific role of FAAH in subjective well-being remains underexplored, particularly with longitudinal data. In our study, we analyzed well-being data collected three years apart using the WHO (Ten) Well-Being Index and genotyped a functional polymorphism in the FAAH gene (rs324420, Pro129Thr) in a sample of 2,822 individuals. We found that the A-allele of rs324420, which results in reduced FAAH activity and elevated anandamide levels, was associated with lower well-being scores at both time points. A subsequent phenome-wide association study (PheWAS) validated our well-being findings in the UK Biobank (N=126,132) and revealed an additional association with alcohol dependence. In our cohort, using lagged longitudinal mediation analyses, we uncovered evidence of an indirect association between rs324420 and problematic alcohol use (AUDIT-P) through the pathway of lower well-being. We propose that lifelong elevated anandamide levels can disrupt the endocannabinoid system – a biological contributor to well-being – potentially leading to increased alcohol intake. Further genetic studies and mediation analyses are needed to validate and extend these findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Alcohol Research Council of the Swedish Alcohol Retailing Monopoly (2020-0080, 2020; P.A.M.), the Royal Physiographic Society in Lund (40581, 2019; P.A.M.), the Lars Hierta Memorial Foundation (FO2019-0331, 2019; P.A.M.), the Ake Wiberg Foundation (M20-0070, 2020; P.A.M.), the Magnus Bergvall Foundation (2020-03641, 2020; P.A.M.), the Sigurd and Elsa Golje Memorial Foundation (LA2020-0191, 2020; P.A.M.), and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet Stockholm County Council (SLL20170292, SLL20190589; C.L.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Karolinska Institutet gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
